RNA
Atrium Therapeutics, Inc.
7.80$
-3.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -22.2% | +61.6% | -42.3% | +14.2% | +27.3% | -47.1% | +144.6% | +224.3% | -93.1% | +2,185.8% | -84.7% | – | |
| – | -98.7% | +4.2% | +7.2% | +3.3% | +3.9% | – | – | – | – | -89.9% | +127.2% | – | |
| – | – | +83.9% | -53.2% | +72.0% | +27.3% | -47.1% | -8,636.4% | – | -93.1% | +2,168.2% | -86.3% | – | |
| – | +10.7% | +26.5% | -4.3% | +20.7% | +23.9% | +4.0% | +38.8% | +12.2% | -88.1% | -9.9% | -7.9% | – | |
| – | +17.4% | -13.8% | +49.2% | +12.3% | +21.8% | +18.6% | +9.7% | -84.3% | +426.5% | -33.4% | -49.3% | – | |
| – | +397.6% | +17.2% | +4.9% | +19.6% | +23.4% | +7.4% | -72.3% | -77.0% | +477.7% | -24.8% | -31.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.